Drugs Used in Erectile Dysfunction

DrugDrug NameDrug Indication
DB00203SildenafilSildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications: (1) the treatment of erectile dysfunction [A175582, L5611, F3853, F3856, F3886]; and (2) treatment of pulmonary hypertension, where: a) the US FDA specifically indicates sildenafil for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening [F3850]. The delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy [F3850]. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%) [F3850]; b) the Canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension (PPH) or pulmonary hypertension secondary to connective tissue disease (CTD) in adult patients with WHO functional class II or III who have not responded to conventional therapy [F3859]. In addition, improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy [F3859]; and c) the EMA product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity [F3883]. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease [F3883]. The EMA label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension [F3883]. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease [F3883].
DB00770AlprostadilFor palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Also for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.
DB00820TadalafilUsed for the treatment of erectile dysfunction.
DB00862VardenafilUsed for the treatment of erectile dysfunction
DB01392YohimbineIndicated as a sympatholytic and mydriatic. Impotence has been successfully treated with yohimbine in male patients with vascular or diabetic origins and psychogenic origins.
DB06237AvanafilTreatment of erectile dysfunction in males.
DB06267UdenafilInvestigated for use/treatment in erectile dysfunction and hypertension.
DB09205MoxisylyteBy the WHO, moxisylyte is indicated for the symptomatic management of sequelae of cerebral infarction or hemorrhage.[T91] The cerebral infarction is characterized by the blockage of the artery either by the formation of a thrombus or an embolus.[A31644] On the other hand, the FDA classified moxisylyte for the reversal of phenylephrine-induced mydriasis in patients who have narrow anterior angles and are at risk of developing an acute attack of angle-closure glaucoma.[L1172] Closed-angle glaucoma is caused by the contact between the iris and the trabecular meshwork. This contact will damage the aqueous outflow by the meshwork thus, increasing eye pressure and producing the symptoms of glaucoma.[A31645] Mydriasis is referred to the dilatation of the pupils and this standard body function is known to be a trigger factor for the development of acute closed-angle glaucoma.This risk is explained by the generation of a pupillary block, which is the contact between the pupillary margins and the lens, thus preventing flow from the aqueous humor to the anterior chamber and followed by an increased pressure gradient.[L1173] Moxisylyte is also approved in France as the first drug for the treatment of impotence.[A31647]
DB00714ApomorphineFor the acute, intermittent treatment of hypomobility, off episodes (end-of-dose wearing off and unpredictable on/off episodes) associated with advanced Parkinson's disease.
DB01113PapaverineFor the treatment of impotence and vasospasms.
DrugDrug NameTargetType
DB00203SildenafilcGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB00203SildenafilCytochrome P450 2C9enzyme
DB00203SildenafilRetinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammatarget
DB00203SildenafilRetinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammatarget
DB00203SildenafilCytochrome P450 3A4enzyme
DB00203SildenafilCytochrome P450 3A5enzyme
DB00203SildenafilCytochrome P450 3A7enzyme
DB00203SildenafilMultidrug resistance-associated protein 4transporter
DB00203SildenafilMultidrug resistance-associated protein 5transporter
DB00203SildenafilMultidrug resistance-associated protein 7transporter
DB00203SildenafilCytochrome P450 2C19enzyme
DB00203SildenafilCytochrome P450 2D6enzyme
DB00203SildenafilCytochrome P450 1A1enzyme
DB00203SildenafilCytochrome P450 2E1enzyme
DB00203SildenafilSolute carrier organic anion transporter family member 1B1transporter
DB00203SildenafilMultidrug resistance protein 1transporter
DB00770AlprostadilProstaglandin E2 receptor EP2 subtypetarget
DB00770AlprostadilProstaglandin E2 receptor EP1 subtypetarget
DB00770AlprostadilMultidrug resistance-associated protein 5transporter
DB00770AlprostadilSolute carrier organic anion transporter family member 2B1transporter
DB00770AlprostadilSolute carrier organic anion transporter family member 3A1transporter
DB00770AlprostadilMultidrug resistance-associated protein 4transporter
DB00770AlprostadilSolute carrier organic anion transporter family member 2A1transporter
DB00770AlprostadilProstaglandin D2 receptor 2target
DB00770AlprostadilSolute carrier family 22 member 6transporter
DB00820TadalafilcGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB00820TadalafilCytochrome P450 3A4enzyme
DB00820TadalafilDual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11Atarget
DB00820TadalafilCytochrome P450 3A5enzyme
DB00862VardenafilcGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB00862VardenafilCytochrome P450 3A4enzyme
DB00862VardenafilRetinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammatarget
DB00862VardenafilRetinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammatarget
DB00862VardenafilCytochrome P450 3A5enzyme
DB00862VardenafilMultidrug resistance protein 1transporter
DB01392YohimbineAlpha-2A adrenergic receptortarget
DB01392YohimbineAlpha-2B adrenergic receptortarget
DB01392YohimbineAlpha-2C adrenergic receptortarget
DB01392Yohimbine5-hydroxytryptamine receptor 1Atarget
DB01392Yohimbine5-hydroxytryptamine receptor 1Btarget
DB01392Yohimbine5-hydroxytryptamine receptor 1Dtarget
DB01392YohimbineD(2) dopamine receptortarget
DB01392YohimbineD(3) dopamine receptortarget
DB01392Yohimbine5-hydroxytryptamine receptor 2Atarget
DB01392Yohimbine5-hydroxytryptamine receptor 2Ctarget
DB01392YohimbineCytochrome P450 2D6enzyme
DB01392YohimbineCytochrome P450 3A4enzyme
DB01392YohimbineATP-sensitive potassium channeltarget
DB01392Yohimbine5-hydroxytryptamine receptor 2Btarget
DB06237AvanafilcGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB06237AvanafilCytochrome P450 3A4enzyme
DB06267UdenafilcGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB06267UdenafilCytochrome P450 3A4enzyme
DB06267UdenafilCytochrome P450 3A5enzyme
DB09205MoxisylyteCholinesteraseenzyme
DB09205MoxisylyteCytochrome p450 3A subfamilyenzyme
DB09205MoxisylyteAlpha adrenergic receptortarget
DB00714ApomorphineD(2) dopamine receptortarget
DB00714ApomorphineD(1A) dopamine receptortarget
DB00714ApomorphineD(4) dopamine receptortarget
DB00714ApomorphineD(3) dopamine receptortarget
DB00714ApomorphineD(1B) dopamine receptortarget
DB00714ApomorphineNeuron-specific vesicular protein calcyontarget
DB00714ApomorphineAlpha-2C adrenergic receptortarget
DB00714ApomorphineAlpha-2B adrenergic receptortarget
DB00714Apomorphine5-hydroxytryptamine receptor 2Ctarget
DB00714Apomorphine5-hydroxytryptamine receptor 1Atarget
DB00714Apomorphine5-hydroxytryptamine receptor 2Atarget
DB00714Apomorphine5-hydroxytryptamine receptor 2Btarget
DB00714ApomorphineAlpha-2A adrenergic receptortarget
DB00714Apomorphine5-hydroxytryptamine receptor 1Dtarget
DB00714Apomorphine5-hydroxytryptamine receptor 1Btarget
DB01113PapaverinecAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB01113PapaverinecAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10Atarget